Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitors, according to a two-year, follow-up analysis of the ICARIA-MM study
However the CD38-directed monoclonal antibody may find it difficult to make its mark in the Australian setting any time soon.
The study, published in The Lancet Oncology, compared isatuximab plus pomalidomide and low-dose dexamethasone with pomalidomide-dexamethasone alone.
Red the full article here: Another CD38 directed therapy shows promise in MM – but will Aussies benefit? (thelimbic.com)
